Comparing KH607 to vortioxetine for major depression
Treatments studied
Part of Mental health clinical trials.
This study tests a new oral medication, KH607, against an existing antidepressant (vortioxetine) to see which is more effective and safer for adults with moderate-to-severe depression. Participants will receive one of the two treatments for several weeks, with the option to continue in a longer-term phase if they respond well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with major depressive disorder (moderate to severe), with your current episode lasting at least 3 months if it is your first, or at least 1 month if you have had depression before.
- Your depression is not accompanied by psychotic features (like delusions or hallucinations), and you do not have other major psychiatric conditions like bipolar disorder, schizophrenia, or an anxiety disorder that is the primary issue.
- You have not had a poor response to two or more different antidepressants in a previous episode, and you are not currently receiving structured psychotherapy (like CBT) or certain other therapies for depression.
- You are willing to stop taking other antidepressants, antipsychotics, mood stabilizers, or sedatives during the trial (after a washout period).
- You are not at high risk for suicide, and you meet certain health criteria (e.g., no significant heart, liver, or kidney problems, no active infections like hepatitis B or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can safely and effectively reduce depression symptoms.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
This study tests a new combination of two medications (dextromethorphan and bupropion) as a treatment for major depressive disorder. It may be an option if you have not already tried many antidepressants that didn't work.
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
This study tests a combination medication (dextromethorphan plus bupropion) to see how it affects brain activity in people with moderate-to-severe depression. Researchers use brain imaging (fMRI) to understand how the drug works and whether it may help relieve depression symptoms.
This trial tests whether vortioxetine helps reduce symptoms of major depression in Japanese teenagers aged 12-17. It compares the study drug to a placebo to see if it is safe and effective.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.